gefitinib has been researched along with Triple Negative Breast Neoplasms in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (76.67) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, JY; Jeong, M; Jo, J; Jung, YS; Kim, H; Kim, SH; Kwak, JH; Taek Han, Y; Yun, H | 1 |
| Abdelmalek, CM; Gehringer, M; Hesse, SS; Hu, Z; Kinnen, FJM; Kronenberger, T; Küblbeck, J; Kudolo, M; Laufer, SA; Malik, A; Niess, R; Witt-Enderby, PA; Zender, L; Zlotos, DP | 1 |
| Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F | 1 |
| Rosengren, RJ; Taurin, S | 1 |
| Altelaar, M; Iskit, S; Peeper, DS; Rontogianni, S; van Doorn, S | 1 |
| Kim, AMJ; Kim, B; Lim, SO; Oh, W; Schwarz, JR; Sun, R | 1 |
| Aubel, C; Bamdad, M; Bignon, YJ; El Guerrab, A; Penault-Llorca, F | 1 |
| Addison, C; Al-Kadi, E; Chambers, J; Dimitroulakos, J; Li, L; Li, X; McGarry, S; Mediratta, K; Phan, A; Sulaiman, A; Wang, L | 1 |
| He, K; Liu, C; Liu, Z; Ma, Q; Ndege, I; Wang, X; Yu, Q; Yu, Z | 1 |
| Baxter, RC; Boyle, FM; de Silva, HC; Julovi, SM; Lin, MZ; Martin, JL | 1 |
| Jafari, M; Kim, J; Lee, JY; Ruiz-Torres, SJ; Sriram, V; Waltz, SE; Zhou, Z | 1 |
| Asselah, J; Badescu, D; Basik, M; Bertos, NR; Blanchet-Cohen, A; Guiot, MC; Kleinman, CL; Liu, L; Meterissian, S; Munoz-Ramos, V; Omeroglu, A; Park, M; Petrecca, K; Ragoussis, J; Revil, T; Saleh, SMI; Savage, P; Wang, YC; Zuo, D | 1 |
| Guo, D; Hu, GN; Huang, BF; Li, X; Li, Y; Long, T; Su, CM; Tang, CH; Wang, CQ; Wang, Q; Wang, Y; Yuan, H; Zhao, YM | 1 |
| Kwak, SJ; Seong, YS; Yi, YW; You, KS | 1 |
| Al-Mahmood, S; Garbuzenko, OB; Minko, T; Sapiezynski, J | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Baxter, RC; de Silva, HC; Lin, MZ; Martin, JL; Scott, CD | 1 |
| Bose, S; Chen, J; Cui, X; Cui, Y; Giuliano, AE; Han, B; Jin, Y; Karlan, BY; Orsulic, S; Wiedemeyer, R; Zhang, X | 1 |
| Boerner, JL; Bollig-Fischer, A; Madden, JM; Mattingly, RR; Mueller, KL; Stemmer, P | 1 |
| Han, J; Jeon, M; Jung, T; Kil, WH; Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Liu, Q; Liu, Z; Song, H; Wang, L; Wang, X; Yu, Q; Yu, Z | 1 |
| Bellizzi, A; Cardone, RA; Forciniti, S; Greco, MR; Paradiso, A; Reshkin, SJ; Rubino, R; Zeeberg, K | 1 |
| Chen, Y; Deng, M; Liu, D; Wang, J; Zhang, L | 1 |
| Bae, EJ; Bae, I; Kwak, SJ; Seong, YS; Yi, YW; You, K | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| He, KW; Huo, ZJ; Liu, ZY; Ma, QH; Song, XG; Wang, XW; Wang, XZ; Yu, ZY; Zhuo, PY | 1 |
| Al-Daccak, R; Antonicelli, F; Bastid, J; Bensussan, A; Cure, H; Fabre, J; Fuselier, C; Garbar, C; Giustiniani, J; Merrouche, Y | 1 |
| Holtrich, U; Karn, T; Kedan, A; Kothari, C; Lev, S; Mills, GB; Müller, AK; Nguyen, LK; Panayotopoulou, E; Selitrennik, M; Shin, S; Verma, N | 1 |
| Emons, G; Girgert, R; Gründker, C | 1 |
| Boerner, JL; Kuperwasser, C; List, K; Madden, JM; Mueller, KL; Zoratti, GL | 1 |
1 review(s) available for gefitinib and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Metastatic and triple-negative breast cancer: challenges and treatment options.
Topics: Animals; Biomarkers, Tumor; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Neoplasm Metastasis; Prognosis; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2018 |
29 other study(ies) available for gefitinib and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2019 |
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Tamoxifen; Triple Negative Breast Neoplasms | 2022 |
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2022 |
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms | 2022 |
Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.
Topics: Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Mass Spectrometry; Oxadiazoles; Protein Kinase Inhibitors; Proteomics; rho-Associated Kinases; Triple Negative Breast Neoplasms | 2020 |
Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
Topics: Animals; Antibodies; Antineoplastic Agents; B7-H1 Antigen; Cell Line; Cell Line, Tumor; Deoxyglucose; Female; Gefitinib; Glucose; HEK293 Cells; Humans; Immunotherapy; Mice; Mice, Inbred BALB C; Triple Negative Breast Neoplasms | 2020 |
Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2020 |
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Metformin; Neoplastic Stem Cells; Triple Negative Breast Neoplasms; Tumor Hypoxia; Up-Regulation | 2020 |
Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer.
Topics: Adenine; Animals; Autophagy; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Macrolides; Mice; Mice, Nude; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Fingolimod Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Insulin-Like Growth Factor Binding Protein 3; Mice; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Lactates; Mice; Nanocapsules; Polyethylene Glycols; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
Topics: Animals; BRCA1 Protein; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Protein Kinase Inhibitors; Quinazolines; RNA, Neoplasm; Sequence Analysis, RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Carrier Proteins; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Microfilament Proteins; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Progression-Free Survival; Triple Negative Breast Neoplasms | 2017 |
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2018 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Eukaryotic Initiation Factors; Female; Gefitinib; HEK293 Cells; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Female; Fibronectins; Gefitinib; Humans; MCF-7 Cells; Phosphorylation; Quinazolines; Signal Transduction; Silybin; Silymarin; Triple Negative Breast Neoplasms; Tyrphostins | 2014 |
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Mice; Phosphatidylinositol 3-Kinase; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
Topics: Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoproteins; Plakins; Protein Transport; Pseudopodia; Quinazolines; Sodium-Hydrogen Exchangers; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Drug Interactions; ErbB Receptors; Female; Gefitinib; Humans; Oligopeptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2015 |
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Indoles; Peptide Library; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Ribosomal Protein S6; Sulfonamides; Triple Negative Breast Neoplasms | 2015 |
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Triple Negative Breast Neoplasms | 2015 |
[Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Macrolides; MCF-7 Cells; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Triple Negative Breast Neoplasms | 2016 |
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Topics: Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-17; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2016 |
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Fluorescent Antibody Technique; Focal Adhesion Kinase 2; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Mice; Nedd4 Ubiquitin Protein Ligases; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2017 |
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Topics: Antineoplastic Agents; Aromatase; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin D1; ErbB Receptors; Estradiol; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Phosphorylation; Quinazolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; src-Family Kinases; Triple Negative Breast Neoplasms | 2017 |
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression; Hepatocyte Growth Factor; Humans; Paracrine Communication; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Triple Negative Breast Neoplasms | 2012 |